智通财经APP获悉，香港联交所最新资料显示，1月7日，梅斯健康(02415)股东将股票由Merrill Lynch Far East Limited转入中国国际金融香港证券，转仓市值8821.08万港元，占比10.53%。
梅斯健康此前发布的2025年中期业绩显示，收益1.25亿元(人民币，下同)，同比增长13.2%；净利润1323.9万元，同比增长5238.3%；每股基本盈利2.45分，拟派中期股息每股1.1港仙。期内，总收益同比增加，主要是由于制药行业复苏，以及国内制药企业对循证驱动型营销模式的加速转型，带动精准全渠道营销解决方案需求增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.